Ladda ner PDF.
Scalp Cooling Technology for Women with Breast Cancer Expands to 67 Medical Centers
Lund, Sweden – March 21, 2017—Dignitana AB, an international leader in medical scalp-cooling technology and the manufacturer of the DigniCap® scalp cooling system, announced today the availability of the DigniCap® system in ten additional sites across the U.S.
The DigniCap® system, which was the first scalp cooling device to complete rigorous FDA clinical trials in America, where seven out of ten patients with early-stage breast cancer kept at least 50% of their hair, will soon be available at ten additional medical centers, making it accessible at a total of 67 U.S. medical centers across 19 states. Results from Dignitana’s multi-center clinical trial were recently published in February 2017 by The Journal of the American Medical Association (JAMA).
“We are thrilled that demand for this revolutionary scalp cooling treatment continues to grow in the U.S.,” said William Cronin, Chief Executive Officer of Dignitana, Inc., the U.S. subsidiary of Dignitana AB. “We are honored to be able to work with so many patient-focused medical centers to make the DigniCap® scalp cooling system easily accessible to breast cancer patients undergoing chemotherapy.”
The following cancer treatment centers are the most recent U.S. sites to include the DigniCap® scalp cooling system as part of their breast cancer treatment and care regimens:
Lake Worth, Florida
San Bernardino, California
New York, New York
Colorado Springs, Colorado
New York, New York
The device features a patented tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.
About Dignitana AB (publ)
Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bank as Certified Advisor. Headquartered in Dallas, Texas, Dignitana, Inc. is the U.S. subsidiary of Dignitana AB. For more information, visit www.dignitana.com.
The information in this press release is such that Dignitana AB must disclose it in accordance with the EU market abuse regulation. The information was submitted, by the above contact, for publication at 09,00 am (CET), March 21, 2017.
King + Company
00 1 212 561-7464
Chairman of the Board
+46 (0)709 312730